Research digest / melanocortin MC4R agonist
PT-141 is a melanocortin MC4R agonist with one approved use, and many that sit outside it.
A measured reading of the bremelanotide record — what the trials and the FDA label establish, exactly where the approval begins and ends, and what the research-chemical form is not.
The short version
PT-141 is the lab name for bremelanotide, a small lab-made peptide (a short chain of amino acids) that acts in the brain. It switches on a brain signal called the melanocortin MC4 receptor — a control point the body normally uses to set sexual desire and appetite. Switching it on can raise the feeling of desire. That is different from how erection pills work; those open up blood flow in the body, while PT-141 works in the brain.
In 2019 the U.S. Food and Drug Administration (the FDA, the agency that approves medicines) approved one prescription form for one use only: low sexual desire that causes distress in women who have not yet reached menopause [7]. Every other use you may read about — in men, in older women, for performance — has not been approved and is still being studied [10]. A separate version sold online as a "research chemical" is not the approved medicine and is not quality-checked [13]. This site reads that record carefully and tells you which is which. The benefits people report, including the downsides, are on PT-141 effects.
What is PT-141
PT-141 is a synthetic cyclic heptapeptide — a ring of seven amino acids — built as an analogue of alpha-MSH (alpha-melanocyte-stimulating hormone, a natural brain signal cut from a larger precursor protein) [1]. Its international nonproprietary name is bremelanotide, and the two names point at the same molecule [10]. It carries the CAS identifier 189691-06-3 and a molecular weight near 1025.2 Da.
What sets PT-141 apart from most peptides discussed online is that it has a genuine, dated regulatory record. The FDA approved bremelanotide injection on June 21, 2019, under NDA 210557 [7]. That approval is narrow: it covers acquired, generalized hypoactive sexual desire disorder (HSDD — persistent, distressing low desire) in premenopausal women, at 1.75 mg given under the skin as needed [10]. The peptide also has a parallel life as an unapproved "research chemical," and the distance between those two existences is the load-bearing fact of this whole page.
PT-141 peptide: a central mechanism, not a vascular one
The PT-141 peptide works in the brain. It activates central melanocortin receptors — chiefly MC4R, with some MC3R activity — that are concentrated in the hypothalamus and limbic system [1]. By stimulating MC4R in circuits such as the medial preoptic area (a hypothalamic region tied to sexual motivation), it is thought to engage dopamine pathways that govern desire [5].
This is a different mechanism from PDE-5 inhibitors, the well-known erection drugs, which act peripherally on blood-vessel smooth muscle. A controlled in-vitro study makes the contrast concrete: alpha-MSH relaxed rabbit vaginal-wall and artery tissue, while bremelanotide at 1 µM did not — consistent with a central, not a peripheral vascular, action [12]. PT-141 does not act through the testosterone (HPG) axis and does not directly raise testosterone; that is a common misconception worth clearing early.
The full mechanism is on the melanocortin receptor agonist page.
What the human trial record actually shows
The strongest human evidence comes from two identical Phase 3 trials known together as RECONNECT (n=1267 premenopausal women with HSDD) [3]. Bremelanotide 1.75 mg as needed produced a statistically significant improvement in sexual desire (integrated FSFI-desire +0.35, P<.001) and reduced desire-related distress (FSDS-DAO item 13 −0.33, P<.001) versus placebo over 24 weeks [3]. A 52-week open-label extension (684 women) showed sustained benefit and no new safety signals [4].
Those are real, replicated findings — and they are modest. Independent re-analyses argue the effect sizes, while significant, are small, and they question how clinically meaningful the chosen outcome measures are [the controversies are catalogued on /effects]. Both things are true at once, and a careful reading holds them together rather than picking one. The benefits people actually report, with the downsides, live on PT-141 effects; the cited evidence is on PT-141 research.
Where the approval begins and ends
This is the boundary the site is built around. The approval covers premenopausal women with HSDD — and nothing else [10]. Use in men, in postmenopausal women, for erectile dysfunction, or for "performance" is off-label or investigational, even though early Phase 2 erectile-dysfunction data exist [1]. The peptide also falls under WADA's non-approved-substances framework (S0) in contexts without current therapeutic approval; athletes should consult current WADA guidance directly.
The "PT-141 research chemical" sold online sits entirely outside the pharmaceutical framework — no regulatory oversight of identity, purity, or concentration [13]. The label also carries hard limits: a warning on transient blood-pressure increases and a contraindication in uncontrolled hypertension or known cardiovascular disease [7]. None of this is presented here as guidance for any individual. It is the record, read straight, with every approval limit marked rather than blurred.